Ocugen’s leadership is taking its case on the road. The biotech said today that executives will appear at two upcoming industry gatherings, including the “H.C. Wainwright: Biotech on Tap 2026” event in Munich on October 1. The European swing is a deliberate move: after months of share-price turbulence and visible caution among U.S. investors, management is out to win back institutional confidence.
There is a concrete reason for the charm offensive. Roughly a week ago, Ocugen adjourned a special shareholder meeting called to vote on expanding its authorized common stock by 250 million shares. The new date for the ballot is October 5, 2026. At the original gathering, only 47.3% of outstanding capital was represented — 160 million shares, measured against the shares outstanding as of the July 27 record date. Without that mandate, the company lacks the financial flexibility it needs for the development phases ahead.
A $10 Price Target, and a Stock Still Down 27% This Year
The push for votes lands alongside a fresh endorsement from Wall Street. H.C. Wainwright raised its price target on Ocugen yesterday from $9.50 to $10.00 and reiterated its “Buy” rating. According to media reports, the analysts were responding to the company’s regulatory progress on its lead candidate, OCU400.
The market’s own verdict has been less enthusiastic. In German trading today the stock changed hands at EUR 0.9110, leaving it down 27% since the start of the year. The shares climbed 4.4% to EUR 0.9480 in an earlier session, but that rebound does little to mask how far the paper sits below its historic marks — it remains 60% off its 52-week high. The gap between the raised target and the subdued European price captures the tension investors are weighing: clinical momentum on one side, unresolved corporate decisions on the other.
Bahamas Nod Sets Up a 90-Day Treatment Window
The regulatory news behind Wainwright’s revision came last Friday. Ocugen disclosed that it had secured a provisional approval and a Priority Designation for OCU400 on the Bahamas. The gene therapy candidate targets retinitis pigmentosa.
Should investors sell immediately? Or is it worth buying Ocugen?
Ocugen intends to make OCU400 available on the islands through an expanded access program, with the goal of delivering the first treatment within 90 days of receiving full approval. The company has also reaffirmed its U.S. timeline: initial Phase 3 results for OCU400 are expected in the first quarter of 2027, with a BLA submission to the U.S. drug regulator planned for the second quarter of 2027.
Those overseas regulatory wins give Ocugen visibility, but the milestones that matter most are still ahead — and until they arrive, the funding requirement stays steep.
The Narrow Path to a Filing
For shareholders, the next few days sharpen an old biotech dilemma. Without fresh capital, clinical programs risk stalling; yet a package this large carries substantial dilution risk. If the authorization to issue new shares fails — whether for lack of a quorum or through resistance from existing holders — the tight schedule running to 2027 comes under threat. If owners approve the capital increase, the financing path opens, at the cost of a potentially heavy dilution effect.
The investor appearances in Munich amount to a dress rehearsal for the October 5 vote. Ocugen has become a case study in how narrow the ridge between clinical progress and balance-sheet reality can be in the biotech sector.
Ad
Ocugen Stock: Buy or Sell?! New Ocugen Analysis from September 29 delivers the answer:
The latest Ocugen figures speak for themselves: Urgent action needed for Ocugen investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from September 29.
Ocugen: Buy or sell? Read more here...
